ANTI-C5 Antibodies Having Improved Pharmacokinetics
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 9 of these applications claim priority to application 61/949,932, filed Mar 7, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,079,949 | ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · High confidence UsedRemaining | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 9,107,861 | Methods of Treating C5 Mediated Complement-Associated Conditions with ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 9,206,251 | Nucleic Acids Encoding ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 9,371,377 | ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · Medium confidence | Alexion Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,663,574 | ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · Medium confidence | Alexion Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,803,007 | ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · Medium confidence | Alexion Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 10,227,400 | Methods of Treating Atypical Hemolytic Uremic Syndrome with ANTI-C5 Antibodies In force · Medium confidence | Alexion Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 10,584,164 | Methods of Treating Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria with ANTI-C5 Antibodies In force · Medium confidence | Alexion Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,434,280 | ANTI-C5 Antibodies Having Improved Pharmacokinetics In force · Medium confidence | Alexion Pharmaceuticals, Inc. | In force | Medium confidence | ||
| Application 17/865,681 | ANTI-C5 Antibodies Having Improved Pharmacokinetics Abandoned Abandoned Jul 18, 2023 | Alexion Pharmaceuticals, Inc. | Abandoned | Abandoned Jul 18, 2023 | ||
| 2 more records in this group · Pro | ||||||
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12.
9 of these are in force and held by Alexion Pharmaceuticals, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.